Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
GEMDOCE
Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer
- NCT04386746 ↗
- Active, not recruiting
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Focused
We haven't built an HCP commentary report on GEMDOCE (gemcitabine plus docetaxel in BCG-naïve non-muscle invasive urothelial carcinoma of the bladder) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on GEMDOCE so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Trial for the Use of Intravesical Gemcitabine and Docetaxel (GEMDOCE) in the Treatment of BCG naïve Non-muscle Invasive Urothelial Carcinoma of the Bladder
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Urothelial Carcinoma Bladder; Bladder Cancer
- Interventions
- Gemcitabine; Docetaxel
- Arms
- Intravesical Gemcitabine/Docetaxel · Experimental
- Enrollment
- 27
- Primary outcomes
- 3-Month Complete Response Rate
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Start
- Jul 29, 2020
- Primary completion
- Oct 4, 2022
- Results posted
- Yes
- Registry record
- NCT04386746 · updated Nov 17, 2025